MDCO - The Medicines Company

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
36.06
-0.94 (-2.54%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close37.00
Open36.95
Bid36.13 x 3100
Ask37.50 x 1800
Day's Range36.06 - 37.21
52 Week Range16.69 - 41.33
Volume802,289
Avg. Volume1,504,173
Market Cap2.859B
Beta (3Y Monthly)1.91
PE Ratio (TTM)N/A
EPS (TTM)-2.88
Earnings DateJul 24, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est57.86
Trade prices are not sourced from all markets
  • Are Insiders Buying The Medicines Company (NASDAQ:MDCO) Stock?
    Simply Wall St.2 days ago

    Are Insiders Buying The Medicines Company (NASDAQ:MDCO) Stock?

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

  • GuruFocus.com3 days ago

    David Einhorn's Greenlight Buys NeuBase Therapeutics Stake

    Shares have dropped 7% Wednesday Continue reading...

  • Melinta (MLNT) Announces Preliminary Product Sales for Q2
    Zacks3 days ago

    Melinta (MLNT) Announces Preliminary Product Sales for Q2

    Melinta (MLNT) announces preliminary sales for the second quarter. However, sales number suggests estimates miss for the quarter. Shares fall.

  • Business Wire3 days ago

    The Medicines Company to Announce Second Quarter 2019 Financial Results on July 24

    The Medicines Company will host a conference call and audio webcast on Wednesday, July 24, 2019 at 8:30 a.m. EDT to discuss its second quarter 2019 financial results and operational developments.

  • MoneyShow12 days ago

    The Medicines Company MDCO- 2019 Top Picks' Mid-Year Update

    John McCamant, editor of The Medical Technology Stock Letter, chose The Medicines Co. (MDCO) as his top speculative idea for 2019. The stock has since risen 90%. Here's his latest update on this biotechnology play.

  • Alnylam Submits MAA in Europe for RNAi Therapeutic Givosiran
    Zacks18 days ago

    Alnylam Submits MAA in Europe for RNAi Therapeutic Givosiran

    Alnylam (ALNY) submits Marketing Authorization Application to the EMA for givosiran in development for the treatment of acute hepatic porphyria.

  • Benzinga20 days ago

    Notable Insider Buys This Past Week: AbbVie, MGM and More

    Health care companies featured prominently in the week's insider purchases. MGM Resorts International (NYSE: MGM) had a director continue to make indirect share purchases this past week. MGM stock rose about 2% in the past week, while the S&P 500 was essentially flat.

  • Benzinga24 days ago

    The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 25) ArQule, Inc. (NASDAQ: ARQL ) Zai Lab Ltd (NASDAQ: ZLAB ...

  • Business Wire24 days ago

    The Medicines Company Announces Pricing of Public Offering of Common Stock

    The Medicines Company (MDCO) (the “Company”) today announced the pricing of a public offering of 4,545,455 shares of its common stock at a public offering price of $33.00 per share. Gross proceeds of the offering are expected to be approximately $150 million, before underwriting discounts and commissions and other transaction expenses. In addition, the underwriters have been granted a 30-day option to purchase from the Company up to an additional 681,818 shares of common stock.

  • Benzinga25 days ago

    The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 24) Global Blood Therapeutics Inc (NASDAQ: GBT ) Krystal ...

  • Business Wire26 days ago

    The Medicines Company Announces Launch of Public Offering of Common Stock

    The Medicines Company (MDCO) (the “Company”) today announced the launch of a public offering of $150.0 million of shares of its common stock. In addition, the underwriters will be granted a 30-day option to purchase from the Company up to an additional $22.5 million of shares of common stock. The Company expects to use the net proceeds of the offering to fund its development of inclisiran and for general corporate purposes.

  • Alnylam Completes Enrollment in Phase III Study of Lumasiran
    Zackslast month

    Alnylam Completes Enrollment in Phase III Study of Lumasiran

    Alnylam (ALNY) completes enrollment in its ILLUMINATE-A phase III study on lumasiran for the treatment of adults and children with primary hyperoxaluria type 1.

  • Markitlast month

    See what the IHS Markit Score report has to say about Medicines Co.

    Medicines Co NASDAQ/NGS:MDCOView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for MDCO with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting MDCO. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding MDCO are favorable, with net inflows of $2.28 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Did Hedge Funds Drop The Ball On Medicines Company (MDCO)?
    Insider Monkeylast month

    Did Hedge Funds Drop The Ball On Medicines Company (MDCO)?

    Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]

  • Signal Says This Drug Stock Isn't Done Climbing
    Schaeffer's Investment Researchlast month

    Signal Says This Drug Stock Isn't Done Climbing

    The Medicines Company has nearly doubled in 2019

  • Alnylam Completes Rolling NDA Submission to FDA for Givosiran
    Zackslast month

    Alnylam Completes Rolling NDA Submission to FDA for Givosiran

    Alnylam (ALNY) completes the rolling NDA submission to the FDA for givosiran, which is being evaluated for the treatment of acute hepatic porphyria.

  • Benzinga2 months ago

    These Bullish Medicines Company Options Trades Suggest More Upside Could Be Coming

    The Medicines Company (NASDAQ: MDCO ) shares traded higher by 2.5 percent on Tuesday and are now up 7.5 percent overall in the past week. At this point, Medicines Company traders are likely considering ...

  • Options Traders Expect Huge Moves in Medicines Company (MDCO) Stock
    Zacks2 months ago

    Options Traders Expect Huge Moves in Medicines Company (MDCO) Stock

    Investors need to pay close attention to Medicines Company (MDCO) stock based on the movements in the options market lately.

  • Alnylam Initiates Phase I Study on Hypertension Candidate
    Zacks2 months ago

    Alnylam Initiates Phase I Study on Hypertension Candidate

    Alnylam (ALNY) initiates phase I study on ALN-AGT, an investigational RNAi therapeutic targeting angiotensinogen for the treatment of hypertension in high unmet need populations.

  • Benzinga2 months ago

    Notable Insider Buys This Past Week: Coty, Zillow and More

    Conventional wisdom says that insiders and 10 percent owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. Zillow Group Inc (NASDAQ: Z) had a director return for more notable indirect share purchases this past week. Zillow's new business in buying and selling homes has helped boost its revenue.

  • Business Wire2 months ago

    The Medicines Company Presents Clinical Data Analyses for Inclisiran at 87th European Atherosclerosis Society Congress

    A combined analysis (N=279) from the Phase 2 ORION-1 and Phase 1 ORION-7 trials, presented during an e-poster session, demonstrated that patients across a range of renal function levels achieved consistent reductions in low-density lipoprotein cholesterol (LDL-C) with no dose adjustment necessary for patients with renal impairment. Results from the Phase 2 ORION-2 pilot study, presented as a late-breaking abstract, showed that inclisiran provided durable reductions in LDL-C levels up to day 180 in patients with homozygous familial hypercholesterolemia (HoFH), a genetic disorder characterized by very high levels of LDL-C and early onset of cardiovascular disease, without the need to increase the dose of inclisiran.

  • Medicines Co. (MDCO) Up 17.1% Since Last Earnings Report: Can It Continue?
    Zacks2 months ago

    Medicines Co. (MDCO) Up 17.1% Since Last Earnings Report: Can It Continue?

    Medicines Co. (MDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.